Amaya Gascó

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó et al. · Clinical Cancer Research · 2014 · 193 citations

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Teresa Morán, Jia Wei, Manuel Cobo et al. · Annals of Oncology · 2014 · 30 citations · Full text

Oncology, Medicine, Pathology +10

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

Mariacarmela Santarpía, Ignacio Magrí, María Sanchez-Ronco et al. · Journal of Translational Medicine · 2011 · 29 citations · Full text

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

Jordi Bertrán-Alamillo, Ana Giménez‐Capitán, Ruth Román et al. · Molecular Cancer · 2023 · 21 citations · Full text

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).

Bob T. Li, Myung‐Ju Ahn, Kōichi Goto et al. · Journal of Clinical Oncology · 2022 · 20 citations

Her2-mutant Nsclc, Tps9137 Background, Medicine +15